Nebivolol Sandoz (Nebivolol Hydrochloride)

Nebivolol, the active ingredient in Nebivolol Sandoz, is a beta‑blocker presented as an oral tablet for oral use. It treats hypertension in adult patients by lowering blood pressure and improving vascular function. GNH USA supplies Nebivolol Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nebivolol is a selective β1‑adrenergic antagonist used in the management of cardiovascular conditions, primarily hypertension. - Hypertension: reduces systolic and diastolic blood pressure, helping to prevent cardiovascular complications in adults.

Nebivolol may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Headache: mild to moderate headache reported. - Dizziness: sensation of light‑headedness, especially on standing. - Fatigue: general tiredness or lack of energy. - Nausea: occasional stomach upset. - Bradycardia: slower than normal heart rate. - Peripheral edema: mild swelling of ankles or feet.

Serious or Rare Side Effects: - Severe bradycardia: markedly low heart rate requiring medical attention. - Hypotension: significant drop in blood pressure causing faintness. - Bronchospasm: airway constriction, particularly in patients with asthma. - Heart block: impaired electrical conduction in the heart. - Allergic reactions: rash, itching, or swelling of face and throat. - Hepatic injury: abnormal liver function tests or jaundice.

Before initiating Nebivolol therapy, several safety considerations should be observed. - Blood pressure monitoring: check baseline and periodic readings. - Cardiac assessment: evaluate heart rate and conduction abnormalities. - Respiratory caution: avoid in uncontrolled asthma or severe COPD. - Renal function: adjust use in patients with significant renal impairment. - Discontinuation: do not stop abruptly; taper under medical supervision. - Store at below 25°C: keep in the original container, protect from moisture and direct sunlight.

Nebivolol can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Other beta‑blockers: additive bradycardia and hypotension. - Calcium channel blockers (verapamil, diltiazem): increased risk of AV block. - Potent CYP2D6 inhibitors (paroxetine, fluoxetine): elevated nebivolol plasma levels. - Clonidine withdrawal: may precipitate severe hypertension. - Non‑selective beta‑agonists: antagonism reduces bronchodilation.

Moderate Interactions (Monitor Closely): - Diuretics: enhanced antihypertensive effect, monitor electrolytes. - NSAIDs: may blunt blood pressure reduction. - Antihypertensives (ACE inhibitors, ARBs): additive blood pressure lowering. - Insulin or oral hypoglycemics: possible masking of hypoglycemia symptoms. - Antidepressants (sertraline, venlafaxine): monitor for dizziness or fatigue.